Drug interactions
Encorafenib + Topotecan
Severity: Moderate
Encorafenib and Topotecan: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib inhibits BCRP in vitro, and topotecan is a BCRP substrate. Topotecan exposure may increase, raising the risk of myelosuppression and gastrointestinal toxicity.
What this interaction means in plain words
Encorafenib and Topotecan can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Encorafenib belongs to Oncology; Topotecan belongs to Oncology.
Why it happens
BCRP inhibition by encorafenib decreases efflux and elimination of topotecan.
What to do
Monitor blood counts and toxicity closely, and consider lowering the topotecan dose if adverse effects increase.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Topotecan, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Topotecan
- Adenovirus types 4 and 7 live + Topotecan Contraindicated
- Amiodarone + Topotecan Major
- Cisplatin + Topotecan Major
- Cobicistat + Topotecan Major
- Cyclosporin + Topotecan Major
- Darunavir + Topotecan Major
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Topotecan?
MediHelp rates the interaction as moderate. Encorafenib and Topotecan can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Encorafenib inhibits BCRP in vitro, and topotecan is a BCRP substrate. Topotecan exposure may increase, raising the risk of myelosuppression and gastrointestinal toxicity.
How serious is the interaction between Encorafenib and Topotecan?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and toxicity closely, and consider lowering the topotecan dose if adverse effects increase.
What other medicines interact with Topotecan?
MediHelp also lists interactions of Topotecan with, for example, Adenovirus types 4 and 7 live, Amiodarone, Cisplatin. The full list is on the Topotecan page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
